Pesicka will replace interim prez & CEO Robert Sledd, who will continue to serve as board chair, the Richmond, Va.-based company said.
Prior to his position as chief commercial officer, Pesicka served as CFO for divisions within Thermo Fisher Scientific, the company said. Before joining Thermo Fisher, Pesicka held corporate finance positions, including divisional CFO, at TRW.
“The board is extremely pleased to welcome Ed as the new CEO of Owens & Minor. Ed is a seasoned senior executive with a deep understanding of distribution, manufacturing and service within our industry. He also has a proven ability to lead performance improvement. During his time at Thermo Fisher Scientific, Ed was responsible for leading a portfolio of businesses focused on distribution, manufacturing and services. He demonstrated his sales and financial acumen and developed a reputation for providing outstanding customer service and driving strong financial results. We are pleased that our process resulted in identifying the ideal CEO,” Sledd said in a press release.
“After a thorough search and careful evaluation of candidates, the Board believes we have found the right leader with practical management and people development skills that align with our strategy. Furthermore, as a man of great integrity, Ed fits well with the Owens & Minor culture, making him an excellent fit for the role. We thank Bob for his willingness to step into the Interim CEO role and look forward to continuing to benefit from his wealth of experience as the chairman of our board,” search committee member & lead director Anne Marie Whittemore said in a prepared statement.
“I’m honored to be appointed to lead Owens & Minor, a company with a rich 137-year history of serving the healthcare industry and providing customers with the solutions they need to deliver exceptional patient care. I am committed to uncovering practical and innovative ways of improving the customer experience and driving value for shareholders. I look forward to working alongside our talented teammates and, together, furthering our mission of serving the healthcare industry across the continuum of care with integrity, dedication, innovation and passion,” Pesicka said in a prepared release.
Prior to joining Xtant Medical, O’Connell served as extremities global marketing VP for Wright Medical (NSDQ:WMGI). O’Connell has also held positions with Stryker (NYSE:SYK), Carl Zeiss Meditec and Hudson Healthcare Partners, Casper, Wyo.-based McGinley said.
“We are proud to announce Carl O’Connell as our new CEO. With his extensive leadership in the medical device industry and commercialization expertise, we are confident he is the right choice to lead McGinley Orthopedics to new levels of growth and success. Carl has served as an advisor to the company for the last 5 years, and we share his enthusiasm for the outlook of the company,” co-founder Dr. Joseph McGinley said in a prepared statement.
“I am excited to lead what has the potential to be a world-class organization and a considerable competitor and innovator in the market. The company has exciting patented technology that will significantly improve safety and surgical outcomes. I look forward to expanding upon our recent successes and continuing to establish the strategic course to take McGinley Orthopedics to the next level,” O’Connel said in a press release.
Contract manufacturing firm Cirtronics said last week that it is lifting current COO Dave Patterson to the position of prez & CEO, with founder and former CEO Gerardine Ferlins staying with the company as chief governance officer and board chair.
Patterson joined Cirtronics in 2010 as global sourcing director and become COO in 2012, the Milford, N.H.-based company said.
“Dave has been an integral part of the Cirtronics leadership team for the last eight years. With his steadfast commitment to the culture of Cirtronics and his years of operational experience, he is well equipped to take on his new role,” Ferlins said in a press release.
“I am humbled and very proud to be part of such a great organization. We are an organization led by a purpose – to be an example of how a company can serve society in an ethical and productive way. I look forward to taking the next steps in this journey together with the whole Cirtronics team,” Patterson said in prepared remarks.
Arens has been serving as interim CFO since May 2018 following the departure of Andrew LaFrence, the Eden Prairie, Minn.-based company said.
“Tim has been an impressive partner to me and an invaluable contributor to our management team and Surmodics’ success during the past eight years. I am personally delighted that he has been formally appointed to the role. Tim’s excellent financial, operational and strategic skills and strong leadership are ideally suited to his new role as we continue to drive our strategic initiatives and financial goals of consistent and profitable long-term growth,” prez & CEO Gary Maharaj said in a press release.
“I am excited to work with a group of dedicated and talented colleagues to accelerate our strategic transformation while continuing to deliver on our operating commitments. Surmodics is well-positioned to execute on our strategic initiatives including the development of highly innovative products that benefit patients. I am looking forward to being part of that journey,” Arens said in prepared remarks.
Magnolia Medical Technologies said earlier this month that it named Matthew Lehr as its new intellectual property special counsel.
Prior to joining Seattle-based Magnolia, Lehr served as head of the IP litigation department at law firm Davis Polk & Wardwell.
“Intellectual property is a critical asset for any innovative medical device company that invests heavily to develop new technologies that drive important paradigm shifts in medicine. In our case, we have invested well over a decade along with significant resources to create the category known as initial specimen diversion to significantly improve sepsis testing accuracy. We will benefit from Matt’s expertise and active participation as we continue to drive hospital adoption of our Steripath platform to prevent blood culture contamination,” CEO Greg Bullington said in a prepared statement.
“I am pleased to work with Magnolia as they commercialize and protect their groundbreaking technologies, which directly improve the quality of care for patients. The company has built an extensive and broad intellectual property foundation that will allow them to maintain appropriate protection in numerous medical device categories in the years to come,” Lehr said in a prepared release.
- Isoray moves Cavanagh III from chief scientific officer, COO positions to chief R&D officer
- Deerfield-Oxeon group looks to place more women in boardrooms
- Alivecor names Dr. Shreibati as chief medical officer
- Anaconda Biomed adds Dr. Huysse as CMO, Vidal as manufacturing director
- Zimmer Biomet taps Puryear as CHRO, senior VP
- CathWorks adds Mousavi as global marketing & strategy VP
- Xtant Medical adds five new sales leads